New Lung Cancer Pill By AstraZeneca Wins Early FDA Approval After mroe than two years of testing on humans, the U.S. FDA has approved a new lung cancer pill for AstraZeneca, a British drugmaker. The once-daily drug targets advanced non-small cell lung cancer, the most common type of lung cancer. by Charity Johnson
Healthy Living/Wellness Avastin Copycat ABP 215 Shows Positive Results In Lung Cancer Study by Katherine Derla
Healthy Living/Wellness AstraZeneca's lung cancer AZD9291 shrinks tumor in 50 percent of patients during trial by Anne Francis